Frontiers Adverse event reporting of the IGF 1R monoclonal antibody teprotumumab: a real world study based on the US food and drug administration adverse event reporting system IGF 1 LR3 does not promote growth in late gestation growth restricted fetal sheep American Journal of Physiology Endocrinology and Metabolism American Physiological Society IGF1 LR3 Peptide Review: Benefits, Before & After, Dose, & More GLP 1 Drugs Could Raise the Risk of Weaker Bones and Gout A Medical Review of IGF 1 LR3 Dosage, Side Effects and Safety Aspects